Salim I Khakoo Selected Research

Therapeutics

1/2023	UK-Wide Multicenter Evaluation of Second-line Therapies in Primary Biliary Cholangitis.
11/2022	Disruption of the NKG2A:HLA-E Immune Checkpoint Axis to Enhance NK Cell Activation against Cancer.
1/2022	KIR2DS2 Expression Identifies NK Cells With Enhanced Anticancer Activity.
1/2021	The role of NK cells in oncolytic viral therapy: a focus on hepatocellular carcinoma.
6/2019	Immunotherapy for hepatocellular carcinoma: Current and future.
1/2019	Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBeAg-negative chronic hepatitis B.
1/2019	The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis.
11/2017	Hepatitis C bio-behavioural surveys in people who inject drugs-a systematic review of sensitivity to the theoretical assumptions of respondent driven sampling.
4/2015	Outcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Salim I Khakoo Research Topics

Disease

16	Infections 01/2022 - 08/2004
11	Neoplasms (Cancer) 01/2024 - 08/2005
10	Virus Diseases (Viral Diseases) 01/2023 - 08/2005
6	Hepatocellular Carcinoma (Hepatoma) 04/2022 - 01/2019
5	Hepatitis C 01/2022 - 04/2010
3	Lymphoma (Lymphomas) 10/2023 - 01/2021
3	Chronic Hepatitis B 01/2022 - 04/2015
3	Liver Diseases (Liver Disease) 01/2019 - 01/2018
2	Fibrosis (Cirrhosis) 01/2023 - 01/2019
2	Viremia 07/2016 - 04/2010
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 10/2023
1	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 01/2023
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2023
1	Lung Diseases (Lung Disease) 01/2023
1	COVID-19 01/2022
1	Melanoma (Melanoma, Malignant) 01/2021
1	Crohn Disease (Crohn's Disease) 01/2020
1	T-Cell Leukemia (Leukemia, T Cell) 01/2020
1	Non-alcoholic Fatty Liver Disease 06/2019
1	Liver Neoplasms (Liver Cancer) 01/2019
1	Human Influenza (Influenza) 01/2018
1	Dengue (Dengue Fever) 01/2017
1	Yellow Fever 01/2017
1	Chronic Hepatitis C 01/2017
1	Hepatitis B 07/2016
1	Communicable Diseases (Infectious Diseases) 02/2015
1	Carcinogenesis 01/2014
1	Persistent Infection 07/2011
1	HIV Infections (HIV Infection) 01/2011
1	Macular Degeneration (Age-Related Maculopathy) 11/2008
1	Vaccinia 01/2006
1	Autoimmune Diseases (Autoimmune Disease) 08/2005

Drug/Important Bio-Agent (IBA)

12	LigandsIBA 01/2021 - 08/2004
6	Peptides (Polypeptides)IBA 01/2022 - 09/2013
6	HLA-C Antigens (HLA-C)IBA 01/2021 - 11/2008
5	KIR ReceptorsIBA 01/2021 - 11/2008
5	HLA Antigens (Human Leukocyte Antigens)IBA 09/2013 - 08/2004
4	Antiviral Agents (Antivirals)IBA 01/2023 - 10/2011
4	Natural Killer Cell ReceptorsIBA 01/2019 - 08/2004
3	CytokinesIBA 01/2024 - 11/2010
3	Proteins (Proteins, Gene)FDA Link 10/2023 - 04/2010
3	RNA (Ribonucleic Acid)IBA 01/2017 - 07/2011
2	selinexorIBA 10/2023 - 01/2021
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2019
2	obinutuzumabIBA 01/2022 - 01/2021
2	Rituximab (Mabthera)FDA Link 01/2022 - 01/2021
2	AntibodiesIBA 01/2021 - 07/2011
2	Interferon LambdaIBA 12/2020 - 11/2020
2	Interleukin-12 (IL 12)IBA 01/2019 - 01/2019
2	nasIBA 01/2019 - 04/2015
1	Chimeric Antigen ReceptorsIBA 01/2024
1	Immune Checkpoint InhibitorsIBA 01/2024
1	ibrutinibIBA 10/2023
1	fibric acidIBA 01/2023
1	Fibric Acids (Fibrates)IBA 01/2023
1	BilirubinIBA 01/2023
1	Alkaline PhosphataseIBA 01/2023
1	SmokeIBA 01/2023
1	Ursodeoxycholic Acid (Urso)FDA LinkGeneric 01/2023
1	Drug CombinationsIBA 11/2022
1	Alanine (L-Alanine)FDA Link 01/2022
1	Amino Acids FDA Link 01/2022
1	TransferasesIBA 01/2022
1	VaccinesIBA 01/2022
1	DNA (Deoxyribonucleic Acid)IBA 01/2021
1	Tumor Suppressor Proteins (Proteins, Tumor Suppressor)IBA 01/2021
1	cyclopropapyrroloindoleIBA 01/2021
1	Hepatitis B e AntigensIBA 01/2019
1	Fluorouracil (Carac)FDA LinkGeneric 01/2019
1	Granzymes (Granzyme)IBA 01/2018
1	HLA-Bw4 antigenIBA 01/2017
1	micaIBA 07/2016
1	Genetic Markers (Genetic Marker)IBA 04/2015
1	HLA-B Antigens (HLA-B)IBA 09/2013
1	Aspartic Acid (Aspartate)FDA Link 09/2013
1	tapasinIBA 09/2013
1	Immunoglobulins (Immunoglobulin)IBA 08/2011
1	KIR2DL3 ReceptorsIBA 07/2011
1	Interferon-gamma (Interferon, gamma)IBA 04/2010
1	NK Cell Lectin-Like Receptor Subfamily CIBA 01/2006

Therapy/Procedure

9	Therapeutics 01/2023 - 04/2015
5	Immunotherapy 04/2022 - 01/2018
1	Ligation 01/2019
1	Duration of Therapy 01/2019
1	Withholding Treatment 04/2015